Table 1.
Demographic and baseline characteristics of patients in relation to treatments.
| Characteristics of subjects | Linfovir® plus, n = 42 (47,2%) | Placebo, n = 47 (52,8%) | p |
|---|---|---|---|
| Male, n (%) Female, n (%) |
21 (50) 21 (50) |
21 (55,3) 26 (44,7) |
n.s. |
| Birth weight, mean (SD) | 2432 (908) | 2250 (909) | n.s. |
| Gestational age at birth, weeks, mean (SD) | 34,6 (3,8) | 34 (4,01) | n.s. |
| Day of life at enrollment, mean (SD) | 102 (66) | 98 (106) | n.s. |
| Maternal age at birth, years, mean (SD) | 32,7 (5,6) | 33,3 (7,1) | n.s. |
| Paternal age at birth, years, mean (SD) | 36,7 (6,8) | 36,5 (7,5) | n.s. |
| HRV positive swab at baseline, n (%) | 20 (47,6) | 18 (38) | n.s. |
| hMPV positive swab at baseline, n (%) | 0 | 1 (2) | n.s. |
| RSV positive swab at baseline, n (%) | 0 | 0 | n.s. |